French national protocol for the management of congenital ichthyosis
Copyright © 2024. Published by Elsevier Masson SAS..
Congenital ichthyoses (CI) comprise a heterogeneous group of monogenic genetic skin diseases characterized by diffuse scaling, often associated with skin inflammation. Diagnosis of the individual form of ichthyosis is complex and is guided by clinical expertise. CI usually has a major impact on quality of life (QOL) and thus requires lifelong treatment. To date, there are no curative therapies, although various symptomatic treatment options exist. The present protocol for the management of CI has been drawn up in accordance with the recommendations published in 2012 by the French National Authority for Health, based on a literature review, with the help and validation of members of the French network for rare skin diseases (FIMARAD). It provides a summary of evidence and expert-based recommendations and is intended to help clinicians with the management of these rare and often complex diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:151 |
|---|---|
| Enthalten in: |
Annales de dermatologie et de venereologie - 151(2024), 1 vom: 09. März, Seite 103247 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Severino-Freire, M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Congenital ichthyosis |
|---|
| Anmerkungen: |
Date Completed 09.04.2024 Date Revised 09.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.annder.2024.103247 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370028880 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370028880 | ||
| 003 | DE-627 | ||
| 005 | 20240409232705.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240323s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annder.2024.103247 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1370.xml |
| 035 | |a (DE-627)NLM370028880 | ||
| 035 | |a (NLM)38513308 | ||
| 035 | |a (PII)S0151-9638(24)00003-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Severino-Freire, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a French national protocol for the management of congenital ichthyosis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.04.2024 | ||
| 500 | |a Date Revised 09.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024. Published by Elsevier Masson SAS. | ||
| 520 | |a Congenital ichthyoses (CI) comprise a heterogeneous group of monogenic genetic skin diseases characterized by diffuse scaling, often associated with skin inflammation. Diagnosis of the individual form of ichthyosis is complex and is guided by clinical expertise. CI usually has a major impact on quality of life (QOL) and thus requires lifelong treatment. To date, there are no curative therapies, although various symptomatic treatment options exist. The present protocol for the management of CI has been drawn up in accordance with the recommendations published in 2012 by the French National Authority for Health, based on a literature review, with the help and validation of members of the French network for rare skin diseases (FIMARAD). It provides a summary of evidence and expert-based recommendations and is intended to help clinicians with the management of these rare and often complex diseases | ||
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Congenital ichthyosis | |
| 650 | 4 | |a Recommendations | |
| 650 | 4 | |a Reference center | |
| 650 | 4 | |a Therapy, PNDS | |
| 700 | 1 | |a Granier Tournier, C |e verfasserin |4 aut | |
| 700 | 1 | |a Chiaverini, C |e verfasserin |4 aut | |
| 700 | 1 | |a Audouze, A |e verfasserin |4 aut | |
| 700 | 1 | |a Morice-Picard, F |e verfasserin |4 aut | |
| 700 | 1 | |a Texier, H |e verfasserin |4 aut | |
| 700 | 1 | |a Dreyfus, I |e verfasserin |4 aut | |
| 700 | 1 | |a Bing-Lecointe, A-C |e verfasserin |4 aut | |
| 700 | 1 | |a Mallet, S |e verfasserin |4 aut | |
| 700 | 1 | |a Bodemer, C |e verfasserin |4 aut | |
| 700 | 1 | |a Fischer, J |e verfasserin |4 aut | |
| 700 | 1 | |a Jonca, N |e verfasserin |4 aut | |
| 700 | 1 | |a Mazereeuw-Hautier, J |e verfasserin |4 aut | |
| 700 | 0 | |a French Pediatric Dermatology Research Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annales de dermatologie et de venereologie |d 1986 |g 151(2024), 1 vom: 09. März, Seite 103247 |w (DE-627)NLM000154113 |x 0151-9638 |7 nnns |
| 773 | 1 | 8 | |g volume:151 |g year:2024 |g number:1 |g day:09 |g month:03 |g pages:103247 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.annder.2024.103247 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 151 |j 2024 |e 1 |b 09 |c 03 |h 103247 | ||